GlobeNewswire Inc.··Telix Pharmaceuticals LimitedTelix Pharma Posts Double-Digit Growth as Pipeline Hits Milestones
Telix Pharma reports 11% Q1 revenue growth to US$230M, reaffirms FY guidance, while advancing prostate and brain cancer pipelines through Phase 3 and regulatory milestones.
TLXFDA approvalclinical trials